Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS)

References

• Wadsten C, Heyman H, Holmqvist M, et al. A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years. Acta Oncol. 2016;55(11):1338–1343. doi: 10.1080/0284186X.2016.1211317.
   PubMed Web of Science ®Google Scholar
• Karlsson P. Postoperative radiotherapy after DCIS: useful for whom? Breast. 2017;34(Suppl 1):S43–S46. doi: 10.1016/j.breast.2017.06.026.
   PubMed Web of Science ®Google Scholar
• Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162–177.
   PubMedGoogle Scholar
• Barrio AV, Van Zee KJ. Controversies in the treatment of ductal carcinoma in situ. Annu Rev Med. 2017;68:197–211. doi: 10.1146/annurev-med-050715-104920.
   PubMed Web of Science ®Google Scholar
• Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–398. doi: 10.1007/s10549-015-3464-6.
   PubMed Web of Science ®Google Scholar
• NHS England. Clinical guidelines for the management of breast cancer. Available from: https://www.england.nhs.uk/mids-east/wp-content/uploads/sites/7/2018/02/guidelines-for-the-management-of-breast-cancer-v1.pdf.
   Google Scholar
• Regionala Cancercentrum I Samverkan. Kunskapsbanken. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/.
   Google Scholar
• Bremer T, Whitworth PW, Patel R, et al. A biological signature for breast ductal carcinoma In situ to predict radiotherapy benefit and assess recurrence risk. Clin Cancer Res. 2018;24(23):5895–5901. doi: 10.1158/1078-0432.CCR-18-0842.
   PubMed Web of Science ®Google Scholar
• Weinmann S, Leo M, Francisco M, et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiation therapy. Clin Cancer Res. 2020;26(15):4054–4063. doi: 10.1158/1078-0432.CCR-19-1152.
   PubMed Web of Science ®Google Scholar
• Wärnberg F, Karlsson P, Holmberg E, et al. Prognostic risk assessment and prediction of radiotherapy benefit for women with ductal carcinoma in situ (DCIS) of the breast, in a randomized clinical trial (SweDCIS). Cancers. 2021;13(23):6103. doi: 10.3390/cancers13236103.
   PubMed Web of Science ®Google Scholar
• Wärnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32(32):3613–3618. doi: 10.1200/JCO.2014.56.2595.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–391. doi: 10.1038/sj.bjc.6602678.
   PubMed Web of Science ®Google Scholar
• McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–715. doi: 10.1200/JCO.2014.57.9029.
   PubMed Web of Science ®Google Scholar
• Lundstedt D, Gustafsson M, Malmström P, et al. Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiother Oncol. 2010;97(2):281–287. doi: 10.1016/j.radonc.2010.09.018.
   PubMed Web of Science ®Google Scholar
• Kim H, Vargo JA, Smith KJ, et al. Cost-Effectiveness analysis of biological signature DCISionRT use for DCIS treatment. Clin Breast Cancer. 2021;21(3):e271–e278. doi: 10.1016/j.clbc.2020.10.007.
   PubMed Web of Science ®Google Scholar
• Royston P, Lambert PC. Flexible parametric survival analysis in stata: beyond the cox model. Texas: StataPress. 2011.
   Google Scholar
• Crowther MJ, Lambert PC. Parametric multi-state survival models: flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. Stat Med. 2017;36(29):4719–4742. doi: 10.1002/sim.7448.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–1252. doi: 10.1200/JCO.2007.12.7969.
   PubMed Web of Science ®Google Scholar
• Chua BH, Link EK, Kunkler IH, et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022;400(10350):431–440. doi: 10.1016/S0140-6736(22)01246-6.
   PubMed Web of Science ®Google Scholar
• McCormick B, Winter KA, Woodward W, et al. Randomized phase III trial evaluating radiation following surgical excision for Good-Risk ductal carcinoma in situ: long-term report from NRG oncology/RTOG 9804. J Clin Oncol. 2021;39(32):3574–3582. doi: 10.1200/JCO.21.01083.
   PubMed Web of Science ®Google Scholar
• Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169(2):359–369. doi: 10.1007/s10549-018-4693-2.
   PubMed Web of Science ®Google Scholar
• Gupta A, Jhawar SR, Sayan M, et al. Cost-Effectiveness of adjuvant treatment for ductal carcinoma in situ. J Clin Oncol. 2021;39(21):2386–2396. doi: 10.1200/JCO.21.00831.
   PubMed Web of Science ®Google Scholar
• Ward MC, Vicini F, Al-Hilli Z, et al. Cost-Effectiveness analysis of no adjuvant therapy versus partial breast irradiation alone versus combined treatment for treatment of low-risk DCIS: a microsimulation. J Clin Oncol Oncol Pract. 2021;17(8):e1055–e1074. doi: 10.1200/OP.20.00992.
   Google Scholar
• Liljegren G, Karlsson G, Bergh J, et al. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol. 1997;8(8):757–763. doi: 10.1023/a:1008230000822.
   PubMed Web of Science ®Google Scholar
• Stokes ME, Thompson D, Montoya EL, et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008;11(2):213–220. doi: 10.1111/j.1524-4733.2007.00226.x.
   PubMed Web of Science ®Google Scholar
• Vitko AS, Martin PA, Zhang S, et al. Costs of breast cancer recurrence after initial treatment for high risk early breast cancer using SEER-Medicare. 44th Annual San Antonio Breast Cancer Symposium; 2022 Dec 6 − 10, San Antonio TX, USA; 2022
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Eur J Health Econ. 2013;14(3):367–372. doi: 10.1007/s10198-013-0471-6.
   PubMed Web of Science ®Google Scholar
• Raldow AC, Sher D, Chen AB, et al. Cost effectiveness of DCISionRT for guiding treatment of ductal carcinoma in situ. JNCI Cancer Spectr. 2020;4(2):pkaa004.
   PubMed Web of Science ®Google Scholar
• Tian Y, Schofield PE, Gough K, et al. Profile and predictors of long-term morbidity in breast cancer survivors. Ann Surg Oncol. 2013;20(11):3453–3460. doi: 10.1245/s10434-013-3004-8.
   PubMed Web of Science ®Google Scholar
• Glynn D, Bliss J, Brunt AM, et al. Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Res Treat. 2023;197(2):405–416. doi: 10.1007/s10549-022-06802-1.
   PubMed Web of Science ®Google Scholar
• Sopik V, Iqbal J, Sun P, et al. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. Breast Cancer Res Treat. 2016;158(2):385–393. doi: 10.1007/s10549-016-3894-9.
   PubMed Web of Science ®Google Scholar
• Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study. J Clin Oncol. 2016;34(11):1190–1196. doi: 10.1200/JCO.2015.65.1869.
   PubMed Web of Science ®Google Scholar
• Burt LM, Ying J, Poppe MM, et al. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast. 2017;35:122–129. doi: 10.1016/j.breast.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Friedrich A-KU, Reisenbichler ES, Heller DR, et al. Characteristics and long-term risk of breast angiosarcoma. Ann Surg Oncol. 2021;28(9):5112–5118. doi: 10.1245/s10434-021-09689-2.
   PubMed Web of Science ®Google Scholar
• Karlsson P, Holmberg E, Samuelsson A, et al. Soft tissue sarcoma after treatment for breast cancer–a Swedish population-based study. Eur J Cancer. 1998;34(13):2068–2075. doi: 10.1016/s0959-8049(98)00319-0.
   PubMed Web of Science ®Google Scholar